REGISTERED NUMBER: 07205080 (England and Wales)

Unaudited Financial Statements for the Year Ended 31st March 2025

for

Herts & Essex Urology Ltd

Page

Balance Sheet

1

Notes to the Financial Statements

3

FIXED ASSETS

Intangible assets

4

-

-

Tangible assets

5

21,605

28,297

21,605

28,297

CURRENT ASSETS

Debtors

6

11,794

21,746

Cash at bank

390,193

354,545

401,987

376,291

CREDITORS

Amounts falling due within one year

7

4,504

3,391

NET CURRENT ASSETS

397,483

372,900

TOTAL ASSETS LESS CURRENT LIABILITIES

419,088

401,197

PROVISIONS FOR LIABILITIES

4,105

5,376

NET ASSETS

414,983

395,821

CAPITAL AND RESERVES

Called up share capital

8

102

102

Share premium

160

160

Retained earnings

414,721

395,559

SHAREHOLDERS' FUNDS

414,983

395,821

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st March 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st March 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 6th October 2025 and were signed on its behalf by:

Dr B S Potluri - Director

1.	COMPANY INFORMATION

Herts & Essex Urology Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number:

07205080

Registered office:

The Lexicon

Mount Street

Manchester

M2 5NT

The presentation currency of the financial statements is the Pound Sterling (£).

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover

Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Revenue from the provision of professional services is recognised on delivery of the service.

Goodwill

Goodwill, being the amount paid in connection with the acquisition of a business in 2011, has been amortised over its estimated useful life of ten years. The goodwill has been written down to nil in these financial statements being the end of its useful life.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings

-

25% on cost

Motor vehicles

-

20% on reducing balance

Tangible fixed assets are included at cost less depreciation and impairment. Depreciation has been computed to write off the cost of tangible fixed assets over their expected useful life as follows:

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to the profit or loss.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2024 - 2 ) .

4.	INTANGIBLE FIXED ASSETS

Franchise

costs

£

COST

At 1st April 2024

and 31st March 2025

926,180

AMORTISATION

At 1st April 2024

and 31st March 2025

926,180

NET BOOK VALUE

At 31st March 2025

-

At 31st March 2024

-

5.	TANGIBLE FIXED ASSETS

Fixtures

and

Motor

fittings

vehicles

Totals

£

£

£

COST

At 1st April 2024

and 31st March 2025

15,092

50,840

65,932

DEPRECIATION

At 1st April 2024

12,825

24,810

37,635

Charge for year

1,486

5,206

6,692

At 31st March 2025

14,311

30,016

44,327

NET BOOK VALUE

At 31st March 2025

781

20,824

21,605

At 31st March 2024

2,267

26,030

28,297

6.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.3.25

31.3.24

£

£

Trade debtors

11,794

3,659

Tax

-

18,087

11,794

21,746

7.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

31.3.25

31.3.24

£

£

Tax

1,253

-

Social security and other taxes

3,241

2,353

Directors' current accounts

10

1,038

4,504

3,391

8.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:

Class:

Nominal

31.3.25

31.3.24

value:

£

£

60

A Ordinary shares

£1

60

60

40

B Ordinary shares

£1

40

40

1

C Ordinary Share

£1

1

1

1

D Ordinary Share

£1

1

1

102

102

The Ordinary A shares confer on the holders the right to vote upon any resolution proposed at any general meeting of the company.

The Ordinary B shares, Ordinary C shares and Ordinary D shares do not confer on the holders the right to vote upon any resolution proposed at any general meeting of the company.

The A, B, C and D shares rank pari passu in respect of dividend and capital distribution rights.

9.	DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 31st March 2025 and 31st March 2024:

31.3.25

31.3.24

£

£

Dr B S Potluri and Mrs S D Potluri

Balance outstanding at start of year

(1,037

)

(733

)

Amounts advanced

26,040

4,367

Amounts repaid

(25,013

)

(4,671

)

Amounts written off

-

-

Amounts waived

-

-

Balance outstanding at end of year

(10

)

(1,037

)

The loan is payable on demand and no interest is charged during the year.

10.

CONTROL